story of the week
AKT Inhibitor MK-2206 in Advanced Breast Cancer With PIK3CA or AKT Mutations, and/or PTEN Loss/PTEN Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Trial of AKT Inhibitor MK-2206 in Patients With Advanced Breast Cancer Who Have Tumors With PIK3CA or AKT Mutations, and/or PTEN Loss/PTEN Mutation
Breast Cancer Res 2019 Jul 05;21(1)78, Y Xing, NU Lin, MA Maurer, H Chen, A Mahvash, A Sahin, A Akcakanat, Y Li, V Abramson, J Litton, M Chavez-MacGregor, V Valero, SA Piha-Paul, D Hong, KA Do, E Tarco, D Riall, AK Eterovic, GM Wulf, LC Cantley, GB Mills, LA Doyle, E Winer, GN Hortobagyi, AM Gonzalez-Angulo, F Meric-BernstamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.